Skip to main content

Table 1 Pathological and clinical characteristics

From: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

Variable All triple negatives; n = 97 (%) Triple negatives with sufficient FU; n = 71 (%)
Age (years)   
<41 24 (25) 18 (25)
41–50 33 (34) 30 (42)
>50 40 (41) 23 (32)
Tumor size (cm)   
≤2.0 34 (35) 23 (32)
>2.0 63 (65) 48 (68)
Number of tumor positive lymph nodes   
0 54 (56) 35 (49)
1–3 29 (30) 26 (37)
>3 14 (14) 10 (14)
Tumor subtype   
Adenoid cystic 4 (4) NA
Apocrine 7 (7) 7 (10)
Ducto-lobular 1 (1) NA
IDC (nos) 81 (83) 63 (89)
ILC 1 (1) 1 (1)
Metaplastic 3 (3) NA
Tumor shape   
Multi-nodular 4 (4) 4 (6)
Stellate 17 (18) 12 (17)
Sharply demarcated/lobulated 76 (78) 55 (76)
Histological grade   
1 2 (2) 2 (3)
2 8 (8) 4 (6)
3 83 (86) 65 (92)
Adenoid cystic carcinoma not graded 4 (4) NA
DCIS component around tumor   
None 79 (81) 56 (79)
Minimal 10 (10) 8 (11)
Moderate 8 (8) 7 (10)
Extensive NA NA
DCIS differentiation grade   
Well 1 (6) 1 (7)
Moderate NA NA
Poor 17 (94) 14 (93)
LCIS component   
None 93 (96) 67 (94)
Present 4 (4) 4 (6)
Vascular invasion   
None 84 (87) 59 (83)
Present 13 (13) 12 (17)
Lymphocytic infiltrate   
None 8 (8) 4 (6)
Minimal 40 (41) 34 (48)
Moderate 33 (34) 25 (35)
Extensive 12 (12) 8 (11)
Adenoid cystic carcinoma not graded 4 (4) NA
Central fibrotic zone   
None 44 (45) 31 (44)
Present 49 (51) 40 (56)
Adenoid cystic carcinoma not graded 4 (4) NA
KRT5/6   
Negative (0% staining) 21 (22) 16 (23)
Positive (> 0% staining) 74 (76) 53 (75)
Unknown 2 (2) 2 (3)
p53   
Negative (< 50% staining) 47 (49) 33 (47)
Positive (> 49% staining) 48 (50) 36 (51)
Unknown 2 (2) 2 (3)
EGFR   
Negative (0% staining) 69 (71) 58 (82)
Positive (> 0% staining) 26 (27) 11 (16)
Unknown 2 (2) 2 (3)
KIT   
Negative (0% staining) 58 (60) 39 (55)
Positive (> 0% staining) 37 (38) 30 (42)
Unknown 2 (2) 2 (3)
Treatment of primary tumor   
Breast-conservation 61 (63) 45 (63)
Mastectomy 36 (37) 26 (37)
Adjuvant radiotherapy   
Yes 85 (88) 65 (92)
No 12 (12) 6 (8)
Adjuvant systemic therapy   
Chemotherapy 47 (48) 37 (52)
Endocrine therapy 13 (13) 11 (15)
Chemotherapy and endocrine therapy 4 (4) 4 (6)
None 33 (34) 19 (27)
Metastasis as first event   
Yes NA 17 (24)
No NA 54 (76)
  1. DCIS, ductal carcinoma in situ; EGFR, epidermal growth factor receptor; FU, follow-up; IDC (nos), infiltrating ductal carcinoma (not otherwise specified); ILC, infiltrating lobular carcinoma; LCIS, lobular carcinoma in situ; NA, not applicable.